Half-life
The result was a compound with a functional half-life of 26-38 minutes — substantially longer than sermorelin, sufficient for once-daily SubQ administration, and with GHRH recep…
Evidence
BLimited human data
FDA-Approved Indication — The Narrow But Important Truth
Approved for: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Period. The approval is specific to HIV-associated lipodystrophy — a metabolic complication of antiretroviral therapy (HAART) where visceral fat accumulates in combination with peripheral fat wasting. The Phase 3 trials that supported approval enrolled HIV-positive patients with this specific phenotype, not otherwise healthy adults with general visceral obesity. The prescribing label contains an explicit statement: tesamorelin 'is not indicated for weight loss management as it has a weight-neutral effect.' Community and anti-aging clinic use vastly extends beyond the approved population. The FDA approval validates the compound's safety and the specific mechanism — it does not validate efficacy in the populations most longevity clinic patients represent.
Egrifta WR — The 2025 Update
FDA approved the F8 formulation (Egrifta WR) in March 2025. Key improvement: requires reconstitution only once per week instead of daily, despite daily injection. The reduced injection volume is less than half of its predecessor Egrifta SV. Bioequivalence to the original F1 formulation confirmed in PK studies. This is the most convenient commercial tesamorelin preparation and represents the current standard for HIV-associated lipodystrophy treatment.
Phase 3 Evidence — The Gold Standard
Two pivotal Phase 3 RCTs: LIPO-010 (n=412) and CTR-1011 (n=404). Both double-blind, placebo-controlled. Primary endpoint: visceral adipose tissue (VAT) measured by CT scan at 26 weeks. Results: statistically significant 15-18% VAT reduction vs placebo across both trials. Pooled analysis by Falutz et al. (2010, JCEM): confirmed the VAT reduction; IGF-1 increased approximately 81% from baseline (from low-normal to upper-normal range); lean body mass increased significantly; triglycerides reduced. Modest glucose and HbA1c elevations documented in a subset of patients.
The Lancet HIV NAFLD Trial
Stanley/Grunfeld et al. (Lancet HIV, 2019): randomized, double-blind trial in 61 HIV-positive adults with NAFLD (hepatic fat fraction ≥5%). Tesamorelin 2 mg/day for 12 months vs placebo. Results: -37% relative reduction in hepatic fat fraction (p=0.02); fibrosis progression in only 10% of tesamorelin patients vs 35% of placebo patients. The only placebo-controlled trial showing a GHRH analog can prevent liver fibrosis progression — in the HIV context.
Cognitive Function Evidence
Baker et al. (2012, JAMA Neurology): controlled trial of GHRH analog in adults over 60 with mild cognitive impairment and healthy older adults. 20 weeks. Improved executive function and a trend toward better verbal memory in tesamorelin-treated subjects. 2024 HIV-specific trial: did not replicate cognitive findings in HIV population. Classification: Grade B — promising signal; inconsistently replicated; active research area.
WADA Status
S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. Banned at all times. Any competitive athlete: absolute prohibition regardless of whether tesamorelin is prescribed for the FDA-approved HIV indication. A Therapeutic Use Exemption (TUE) would be required even for legitimate HIV lipodystrophy treatment in a tested athlete.